SIV Envelope Trimer Engineering for V2-Apex bnAb Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HIV vaccines face challenges in eliciting broad neutralizing antibodies (bnAbs) due to immune evasion strategies and extreme sequence variability of the HIV envelope glycoprotein (Env), making it difficult to generate effective immune responses.
Innovation Solution
Engineered molecules derived from SIV isolates, such as the MT145K trimer, are designed to mimic specific epitopes like the V2 apex, which bind to broadly neutralizing antibodies, including germline or germline-reverted antibodies, and are administered in immunization strategies to stimulate a robust immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HIV envelope glycoprotein (Env) is used as vaccine immunogen, then immune response is stimulated, but immune evasion and sequence variability prevent broad neutralizing antibody production
Solution Approach 1:
The patent creates simplified copy models of the V2 apex epitope using SIV-derived sequences that replicate the critical structural features (glycan at N160 and basic residues at 166-171) without the full complexity of native HIV Env. These copy models serve as reliable immunogens that consistently elicit bnAbs across different HIV strains despite HIV's sequence variability.
Solution Approach 2:
The invention focuses exclusively on the critical local region (V2 apex epitope) rather than the entire Env protein. By isolating and optimizing this specific 15-amino acid region with its glycan and basic residue pattern, the patent achieves reliable bnAb induction while ignoring the variable regions that cause immune evasion.
2Measurement precision
If SIV-derived epitope models are used to mimic V2 apex structure, then germline antibody binding is achieved, but structural simplification may reduce immunogenicity
Solution Approach 1:
The patent extracts only the essential components of the V2 apex epitope (the 15-amino acid sequence with glycan at N160 and basic residues) from the complete Env structure. This extraction creates a simplified model that maintains precise binding specificity for germline bnAbs while reducing overall structural complexity to manageable levels.
Solution Approach 2:
The invention modifies key parameters of the epitope structure, specifically engineering the glycan at N160 and the basic residue pattern (166-171) to match conserved HIV sequences. These parameter changes ensure precise germline antibody binding while the simplified 15-residue length makes the structure more manageable for vaccine design.
3Productivity
If immunization with engineered trimers is administered, then V2-apex-specific neutralizing antibodies are induced, but immune response may be strain-specific rather than broad
Solution Approach 1:
The patent designs the SIV-derived epitope model to be universal across different HIV strains by focusing on the highly conserved V2 apex region. The engineered trimer structure presents this universal epitope in a standardized format that can be recognized by bnAbs against multiple HIV clades, achieving multi-functionality despite the simplified design.
Solution Approach 2:
The invention performs preliminary engineering of the epitope sequence to pre-establish cross-strain recognition features. By designing the 15-amino acid sequence with conserved glycan and basic residue patterns before immunization, the vaccine is pre-configured to induce bnAbs that will recognize multiple HIV strains, rather than relying on post-immunization adaptation.
Data Source
AI summary
The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention.